How many acquisitions has Lilly made so far?

Lilly has completed 33 acquisitions so far, with an average acquisition amount of $1.64B.

Which countries does Lilly usually acquire in?

Lilly has made acquisitions in 5 countries with the most activity in United States and Canada.

Which is Lilly's latest acquisition?

Lilly's most recent acquisition is CrossBridge Bio, a Developer of Antibody-Drug Conjugate therapeutics, acquired in April 2026.

Which sectors does Lilly target for acquisitions?

Most of Lilly's acquisitions are in Oncology (10) and Neurology (8).

In which year did Lilly make the most acquisitions?

Lilly was most active in 2023, with 6 acquisitions completed in that year.

List of 33 Acquisitions by Lilly (Apr 2026)

Lilly has made a total of 33 acquisitions. Peak acquisition years include 2023 with 6, 2026 with 4, and 2025 with 3. Activity spans 5 countries, with the highest counts in United States (28), Canada (2), and United Kingdom (1). These acquisitions cover 26 sectors, prominently Oncology (10), Neurology (8), and Immunotherapy (6). Over the last five years (2020–2025), the average number of acquisitions per year has been 2.8, and 4 have been completed so far in the current calendar year. The most recent acquisition was CrossBridge Bio, a Houston-based developer of Antibody-Drug Conjugate therapeutics, founded in 2023. This acquisition was completed in April 2026.

Here's the year on year acquisition history of Lilly:

Number of Total Acquisitions

Year	# Acquisitions
2026	4
2025	3
2024	2
2023	6
2022	2
2021	1
2020	3
2019	1
2018	2
2017	1
2016	1
2014	1
2011	1
2010	2
2008	2
2007	1

View all Acquisitions by Lilly

Recent acquisitions by Lilly

Lilly's most recent acquisition - CrossBridge Bio is a Developer of Antibody-Drug Conjugate therapeutics, founded in 2023 and located in Houston. Lilly acquired it in April 2026.

Here is the list of all acquisitions by Lilly sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Apr 14, 2026	CrossBridge Bio	Undisclosed	-	49	989
Mar 31, 2026	Centessa Pharmaceuticals	Undisclosed	Morgan Stanley, Kirkland & Ellis ... and 3 more	25	487
Feb 09, 2026	Orna	$2.4B	-	61	620
Jan 07, 2026	Ventyx Biosciences	$1.2B	Bank of America, Ropes & Gray ... and 3 more	76	277
Oct 24, 2025	Adverum Biotechnologies	Undisclosed	Ropes & Gray, Aquilo Partners ... and 1 more	11	543